Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Study Information
Alliance Study ID: A091105
NCT Study ID (ClinicalTrials.gov): NCT02066181
Alliance Committee: Experimental Therapeutics
Disease or Cancer Type: Solid Tumors
Alliance Study Chair: Mrinal M Gounder
Status: COMPLETED
Study Description
This randomized phase III trial compares the effects, good and/or bad, of sorafenib tosylate in treating patients with desmoid tumors or aggressive fibromatosis. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. [Funding Source – FDA OOPD]
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information